TABLE 1.
Clinicopathological and treatment characteristics of study cohort.
| Characteristics | Overall (n=322), n (%) | TAD (n=85), n (%) | TAD + ALND (n=152), n (%) | ALND (n=85), n (%) |
|---|---|---|---|---|
| Age (year) | ||||
| Median (range) | 47 (20–70) | 47 (28–70) | 46.5 (20–69) | 48 (29–69) |
| Menopausal status | ||||
| Premenopausal | 173 (53.7) | 40 (47.1) | 94 (61.8) | 39 (46.3) |
| Menopausal | 149 (46.3) | 45 (52.9) | 58 (38.2) | 46 (53.7) |
| Time period at surgery | ||||
| 2014–2016 | 128 (39.8) | 17 (20.0) | 94 (61.8) | 17 (21.3) |
| 2017–2018 | 99 (30.7) | 21 (24.7) | 33 (21.7) | 35 (37.5) |
| 2019–2021 | 95 (29.5) | 47 (55.3) | 25 (16.5) | 33 (41.2) |
| Clinical T stage | ||||
| 1a | 44 (13.6) | 18 (21.2) | 21 (13.8) | 5 (5) |
| 2 | 209 (64.0) | 52 (61.2) | 100 (75.8) | 57 (67.5) |
| 3 | 55 (17.1) | 13 (15.3) | 26 (17.1) | 16 (20.0) |
| 4 | 14 (4.3) | 2 (2.3) | 5 (3.3) | 7 (7.5) |
| Clinical N stage | ||||
| 1 | 269 (83.5) | 76 (89.4) | 128 (84.2) | 65 (76.5) |
| 2–3 | 53 (16.5) | 9 (10.6) | 24 (15.8) | 20 (23.5) |
| Biologic subtype | ||||
| ER+/HER2− | 87 (27.0) | 11 (12.9) | 39 (25.7) | 37 (43.5) |
| ER+/HER2+ | 81 (25.2) | 29 (34.1) | 37 (24.3) | 15 (17.6) |
| ER−/HER2+ | 88 (27.3) | 25 (29.4) | 44 (28.9) | 19 (22.4) |
| ER−/HER2− | 66 (20.5) | 20 (23.5) | 32 (21.1) | 14 (16.5) |
| Ki67 | ||||
| <20% | 34 (10.6) | 4 (4.7) | 18 (11.8) | 12 (13.8) |
| ≥20% | 288 (89.4) | 81 (95.3) | 134 (88.2) | 73 (86.2) |
| NACT regimen | ||||
| Anthracycline/taxanes | 112 (34.8) | 31 (36.5) | 43 (28.3) | 38 (42.5) |
| Carboplatin/paclitaxel | 169 (52.5) | 48 (56.5) | 89 (58.6) | 32 (38.8) |
| Other | 41 (12.7) | 6 (7.0) | 20 (13.1) | 15 (18.7) |
| Neoadjuvant anti-HER2 therapy | ||||
| Trastuzumab | 124 (38.5) | 35 (41.2) | 65 (42.8) | 24 (28.2) |
| Trastuzumab + Pertuzumab/Pyrotinib | 45 (14.0) | 19 (22.4) | 16 (10.5) | 10 (11.8) |
| Clinical N stage after NACT | ||||
| ycN0 | 242 (75.2) | 76 (89.4) | 121 (79.6) | 45 (52.9) |
| ycN+ | 80 (24.8) | 9 (10.6) | 31 (20.4) | 40 (47.1) |
| SLN mapping agent | ||||
| Single | 170 (52.8) | 60 (70.6) | 110 (72.3) | 0 |
| Dual | 67 (20.8) | 25 (29.4) | 42 (27.7) | 0 |
| Not used | 85 (26.4) | 0 | 0 | 85 (100.0) |
| Breast surgery | ||||
| Lumpectomy | 112 (34.8) | 47 (55.3) | 48 (31.6) | 17 (20.0) |
| Mastectomy | 210 (65.2) | 38 (44.7) | 104 (68.4) | 68 (80.0) |
| Breast pCR | ||||
| Yes | 141 (40.1) | 58 (68.2) | 67 (44.1) | 16 (18.8) |
| No | 181 (59.9) | 27 (31.8) | 85 (55.9) | 69 (81.2) |
| Axillary pCR | ||||
| Yes | 168 (52.2) | 75 (88.2) | 70 (46.1) | 23 (28.8) |
| No | 154 (47.8) | 10 (11.8) | 82 (53.9) | 62 (71.2) |
| ITCs only | 3 (0.9) | 2 (2.4) | 1 (0.7) | 0 |
| Micrometastases only | 16 (5.0) | 5 (5.9) | 11 (7.2) | 0 |
| Macrometastases | 135 (41.9) | 3 (3.5) | 70 (46.1) | 62 (71.2) |
ALND, axillary lymph node dissection; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; ITC, isolated tumour cell; NACT, neoadjuvant chemotherapy; pCR, pathologic complete response; SLN, sentinel lymph node.
a
Including four cases of occult breast cancer.